TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03690947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Ranibizumab
Description: All subjections received 3 initial Ranibizumab injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Ranibizumab
Description: All subjections received 3 initial Ranibizumab injections

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micropulse Laser
Description: After 3 initial Ranibizumab injections, Micropulse Laser will be done as needed each month if macular edema persists

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Ranibizumab as needed
Description: After 3 initial Ranibizumab injections, Ranibizumab will be injected as needed till BCVA reaches stabilization
Study: NCT03167541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test
Description: RB naproxen sodium tablets (2x220mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test
Description: RB naproxen sodium tablets (2x220mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference
Description: Aleve naproxen sodium tablets (2x220mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference
Description: Aleve naproxen sodium tablets (2x220mg)
Study: NCT03464890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P926 - LICHTENA DermAD CREMA VISO
Description: The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P927 - LICHTENA DermAD CREMA CORPO
Description: The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P926 - LICHTENA DermAD CREMA VISO - PLACEBO
Description: The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated control area
Description: Untreated skin area of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
Study: NCT03079557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intragastric botulinum toxin type A
Description: 200 units Botulinum toxin A (Allergan) injected intragastrically in the antrum every six months
Study: NCT02905825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreathID® Hp System
Description: Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BreathID® Hp Lab System
Description: Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
Study: NCT00417404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aquasol A
Description: 10,000 IU three times weeks, by intramuscular injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham injection
Description: sham injection
Study: NCT02905825

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stool Test
Description: Each subject was asked to perform a stool test in parallel to the breath test.
Study: NCT01308359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV glucose 5%
Description: 500 ml glucose 5% within 30 minutes
Study: NCT03543527

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01523223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Undergo CD8 memory T-cell infusion
Study: NCT02208232

Intervention type: PROCEDURE
Intervention: cataract surgery
Description: cataract surgery with implantation of intraocular lens
Study: NCT04016441

Intervention type: OTHER
Intervention: Survey
Description: Participants will complete a survey online
Study: NCT02575911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond Laser System
Description: Used for the creation of a corneal flap in patients undergoing LASIK surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASIK surgery
Study: NCT03664518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: subjects will initiate treatment with 25 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts. and maximum dose should not exceed 75 mg daily. Subjects whose platelet count between 50\~150×109/L，the eltrombopag dose Maintain. platelet count between 150\~250×109/L, need to reduce the dose of eltrombopag to the next lower dose or lower frequency. Subjects whose platelet count exceeds 250×109/L at any point during the treatment period, must have eltrombopag interrupted and increase the frequency of platelet monitoring to twice weekly, until platelet counts fall below 100×109/L.
Study: NCT03775720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Based on their genetic risk, participants are given advice to either adhere to general dietary guidelines related to salt intake or to reduce their salt intake to no more than 4 grams per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Based on their genetic risk, participants are given advice to either adhere to general dietary guidelines related to salt intake or to reduce their salt intake to no more than 4 grams per day.
Study: NCT03418090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 129Xe MRI
Description: Evaluation of pulmonary function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 129Xe MRI
Description: Evaluation of pulmonary function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 133XE scintigraphy
Description: Evaluation of pulmonary function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 133XE scintigraphy
Description: Evaluation of pulmonary function
Study: NCT01751763

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: treatment (including dose, duration, modification) decided by the investigator.
Study: NCT02100202

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioTurmin (Curcuma longa rhizomes extract)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioTurmin-WD (Water dispersible curcuminoids)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MaQxan (Tagetes erecta flower extract)
Study: NCT01431651

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics,digestive enzyme
Description: patients was randomized into 3 groups: clostridium butyricum MIYAIRI group (80 mg daily) bifidobacterium Longum BB536 group (2 packs daily) biotase:4 tables per day
Study: NCT01872078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4901 (oral)
Description: Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
Study: NCT04452253

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS128
Description: PS128 belongs to Lactobacillus plantarum subsp. plantarumand. Probiotic capsules contain 10 billion CFU (colony forming units) of PS128

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS23 live
Description: PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS23 heat-treated
Description: The PS23 heat-treated probiotic capsule contain 10 billion of PS23 cells.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsule contains microcrystalline cellulose.
Study: NCT04193306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab 150 mg s.c. every 2 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo s.c. every 2 weeks
Study: NCT00242619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: Rosiglitazone was administered at two different doses over the 12-week period.
Study: NCT00639847

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-home asthma management program (AMP) provided by nurses
Description: The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-home asthma management program (AMP) provided by respiratory therapists
Description: The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
Study: NCT04241991

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Active laser
Description: Participants will receive laser irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the irradiation on eight points distributed over the muscle belly, using a gallium arsenide aluminum (Ga-As-Al) laser (λ: 808 nm) equipment. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo laser
Description: Participants will receive placebo irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the placebo irradiation on eight points distributed over the muscle belly. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
Study: NCT00117208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mannitol
Description: 400mg BD for 12 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: mannitol + pulmozyme
Description: combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dornase alpha
Description: 2.5mg daily for 2 weeks
Study: NCT01872078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4901 (oral)
Description: Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4901 (oral)
Description: Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match AZD4901
Description: Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
Study: NCT01392638

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Sugar pills: 37.5, 50.0, and 100.0 mg each 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: Sildenafil pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
Study: NCT03984292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Teaching of laparoscopic skills on a box simulator
Description: The students shall be trained a laparoscopic simulator for a variable duration and the outcome shall be compared.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Teaching of laparoscopic skills on a box simulator
Description: The students shall be trained a laparoscopic simulator for a variable duration and the outcome shall be compared.
Study: NCT01864850

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard RT
Description: 70 Gy / 7 weeks / 2 Gy per fraction

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated RT
Description: 55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
Study: NCT01308359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: saline
Study: NCT03667989

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Assessment of cardiac sympathetic innervation by 123I-MIBG
Description: Assessment of cardiac sympathetic innervation by 123I-MIBG CZT SPECT
Study: NCT04422691

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: After verbal consent the enrolled patients' lungs are evaluated with ultrasound while in isolation. The lungs are divided into 3 fields and findings are categorized according to Soldati et al., 2020.
Study: NCT01807325

Intervention type: PROCEDURE
Intervention: pancreas biopsy
Description: patients who are already having a pancreas biopsy will be invited to enroll. After obtaining enough tissue for usual medical care, we will divert some tissue for the study.
Study: NCT03710356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol 200 MG
Description: DANAZOL 200 mg as capsules 800 mg/d orally, in 2 doses Duration of treatment: 12 months
Study: NCT02076854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-Message Intervention
Study: NCT01035034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid MIDCAB/PCI
Description: MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia. PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with DES
Description: Polymer-based Sirolimus-Eluting Stents (SES)
Study: NCT02789215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proposed Meal Changes for CACFP: Impact on Child Food Intake and Costs
Study: NCT00873613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of Non-dilated retinal photography
Description: Kowa Non-Myd alpha-D Non-dilated fundus camera will be used to obtain photographs.
Study: NCT04536051

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 single dose + paracetamol
Description: Single dose of ChAdOx1nCOV19 vaccine, 5x10\^10 vp + paracetamol

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY single dose + paracetamol
Description: Single dose of MenACWY + paracetamol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 two dose + paracetamol
Description: Two dose of ChAdOx1 nCoV-19 vaccine, 5x10\^10vp (prime) and 0.5mL boost (3.5 - 6.5 × 10\^10 vp), 4-12 weeks apart + paracetamol

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY prime & saline placebo boost + paracetamol
Description: MenACWY prime, and Saline Placebo boost (0.5mL) + paracetamol
Study: NCT02661659

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Multipeptide vaccine S-588210

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Multipeptide vaccine S-588210
Study: NCT00966329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Description: HAART regimen including 2 NRTI/NtRTIs plus maraviroc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: HAART regimen including 2 NRTI/NtRTIs plus one of the following :~* 1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)~* or ATV/unboosted (in a regimen without tenofovir)~* or 1 NNRTI (nevirapine or efavirenz).
Study: NCT04052347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision-making with a Decision-aid
Description: A tablet computer-based decision-aid was developed by the study investigators based on the standards of the International Patient Decision Aid Standards Collaboration9

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine shared decision-making
Description: control group
Study: NCT00194610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Botox 25 international units per injection injected in two places in the bladder neck, with option to inject two other tender points with 25 units each

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal saline injected into the bladder neck via the perineum, 1 cc each given at positions 3 o'clock and 9 o'clock
Study: NCT03765580

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish
Description: Lunch containing fish

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish
Description: Lunch containing fish

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Lunch containing no fish
Study: NCT05663008

Intervention type: PROCEDURE
Intervention: 128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)
Description: 128 electrode EEG and 8 bipolar EMG or HD-EMG will be noninvasively recorded from electrodes placed in a montage over the scalp and arm muscles while the participant is resting or performing tasks designed to engage specific cortical networks of interest (cognitive, behavioural, motor and sensory)

Intervention type: PROCEDURE
Intervention: 128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)
Description: 128 electrode EEG and 8 bipolar EMG or HD-EMG will be noninvasively recorded from electrodes placed in a montage over the scalp and arm muscles while the participant is resting or performing tasks designed to engage specific cortical networks of interest (cognitive, behavioural, motor and sensory)

Intervention type: PROCEDURE
Intervention: 128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)
Description: 128 electrode EEG and 8 bipolar EMG or HD-EMG will be noninvasively recorded from electrodes placed in a montage over the scalp and arm muscles while the participant is resting or performing tasks designed to engage specific cortical networks of interest (cognitive, behavioural, motor and sensory)

Intervention type: PROCEDURE
Intervention: 128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)
Description: 128 electrode EEG and 8 bipolar EMG or HD-EMG will be noninvasively recorded from electrodes placed in a montage over the scalp and arm muscles while the participant is resting or performing tasks designed to engage specific cortical networks of interest (cognitive, behavioural, motor and sensory)
Study: NCT00703963

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INRatio monitor by Hemosense
Description: Home testing monitor to test patients INR by placing a capillary drop of blood from the finger onto a test strip. The test strip is then inserted into the INRatio point-of-care self-testing coagulometer. After approximately 2 minutes of analysis, the INR value will be presented on the meter's display.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care is defined as that care currently received by patients into whom mechanical heart valves are placed. Typically, these patients undergo frequent checks of their INR level until the therapeutic range is achieved. Then periodic INR levels are drawn at the discretion of the managing physician.
Study: NCT03410719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hi GI
Description: subjects will consume the same quantities of metabolizable CHOs (270 g/d) with 135 g of CHOs assigned to the GI intervention foods. The 135 g of CHOs will be distributed as 35 g GI breakfast product, 40 g GI lunch product, and 60 g GI dinner product. Assuming an average 2400 kcal/d total energy requirement among subjects, the 270 g/d metabolizable CHO equates to 40% of total energy intake (1080 kcal/d). One-half of daily CHO intake (135 g/d) will be the same between the Hi-GI and Low-GI groups, including CHOs in fruits, vegetables, and other foods that all subjects will consume. The other one-half of daily CHO intake (135 g) will be different between the Low-GI and Hi-GI groups. Specifically, the GI values of these foods will either be \<55 (Low-GI group) or \>70 (Hi-GI group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hi GI
Description: subjects will consume the same quantities of metabolizable CHOs (270 g/d) with 135 g of CHOs assigned to the GI intervention foods. The 135 g of CHOs will be distributed as 35 g GI breakfast product, 40 g GI lunch product, and 60 g GI dinner product. Assuming an average 2400 kcal/d total energy requirement among subjects, the 270 g/d metabolizable CHO equates to 40% of total energy intake (1080 kcal/d). One-half of daily CHO intake (135 g/d) will be the same between the Hi-GI and Low-GI groups, including CHOs in fruits, vegetables, and other foods that all subjects will consume. The other one-half of daily CHO intake (135 g) will be different between the Low-GI and Hi-GI groups. Specifically, the GI values of these foods will either be \<55 (Low-GI group) or \>70 (Hi-GI group).
Study: NCT03149159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given every 21 days for the first 12 weeks at a dose of 3mg/kg. After 12 weeks, the dose will be 240mg and will be given every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be given at a dose of 1mg/kg every 21 days for up to 12 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Steriotactic radiation therapy
Description: The dose of radiation will be 6 Gy daily x 5 days. Radiation will be given between the first and second doses of ipilimumab plus nivolumab.